Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06714136

The Role of miRNA in Group 3 Pulmonary Hypertension

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
27 (actual)
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

This study recognizes the substantial value of lung tissue obtained from explanted lungs for fundamental research purposes.By analyzing pulmonary tissue affected by pulmonary hypertension, it is possible to discover shared pathogenetic mechanisms between these two groups and to gain a deeper understanding of the mechanisms underlying pulmonary hypertension.

Detailed description

Lung transplantation serves as the sole therapeutic approach targeting the enhancement of life expectancy and quality of life for individuals afflicted with advanced parenchymal or vascular lung diseases. The current study aligns with this objective, recognizing the substantial value of lung tissue obtained from explanted lungs for fundamental research purposes. By investigating lung tissue affected by both group 3 and group 1 pulmonary hypertension, it becomes possible to uncover shared pathogenic mechanisms between these two groups and gain a more profound understanding of the underlying mechanisms driving group 3 pulmonary hypertension. Furthermore, delving into the cells responsible for the expression of dysregulated miRNAs offers the potential to identify novel target mechanisms for the clinical management of group 3 pulmonary hypertension, an area currently limited in therapeutic options. Through a comparative analysis of the quantitative expression patterns of each miRNA among distinct groups, it becomes feasible to determine the extent of involvement of specific pathogenic pathways in the various forms of pulmonary hypertension. Consequently, this approach provides guidance for future research, directing focus towards the most relevant mechanisms of interest.

Conditions

Timeline

Start date
2022-10-10
Primary completion
2023-12-20
Completion
2024-12-20
First posted
2024-12-03
Last updated
2024-12-05

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT06714136. Inclusion in this directory is not an endorsement.